These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 11902305)

  • 1. Effect of hydroxyurea therapy on resting energy expenditure in children with sickle cell disease.
    Fung EB; Barden EM; Kawchak DA; Zemel BS; Ohene-Frempong K; Stallings VA
    J Pediatr Hematol Oncol; 2001 Dec; 23(9):604-8. PubMed ID: 11902305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.
    Estepp JH; Smeltzer MP; Kang G; Li C; Wang WC; Abrams C; Aygun B; Ware RE; Nottage K; Hankins JS
    Am J Hematol; 2017 Dec; 92(12):1333-1339. PubMed ID: 28913922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.
    Hoppe C; Vichinsky E; Quirolo K; van Warmerdam J; Allen K; Styles L
    J Pediatr Hematol Oncol; 2000; 22(4):330-4. PubMed ID: 10959903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia.
    Jayabose S; Tugal O; Sandoval C; Patel P; Puder D; Lin T; Visintainer P
    J Pediatr; 1996 Oct; 129(4):559-65. PubMed ID: 8859263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease.
    Gordeuk VR; Campbell A; Rana S; Nouraie M; Niu X; Minniti CP; Sable C; Darbari D; Dham N; Onyekwere O; Ammosova T; Nekhai S; Kato GJ; Gladwin MT; Castro OL
    Blood; 2009 Nov; 114(21):4639-44. PubMed ID: 19724057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
    Okam MM; Ebert BL
    Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia.
    Zahr RS; Hankins JS; Kang G; Li C; Wang WC; Lebensburger J; Estepp JH
    Am J Hematol; 2019 Jan; 94(1):E27-E29. PubMed ID: 30359463
    [No Abstract]   [Full Text] [Related]  

  • 9. Hydroxyurea and new agents for the treatment of sickle cell disease.
    Rodgers GP
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):713-5. PubMed ID: 16163257
    [No Abstract]   [Full Text] [Related]  

  • 10. Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea.
    Green NS; Ender KL; Pashankar F; Driscoll C; Giardina PJ; Mullen CA; Clark LN; Manwani D; Crotty J; Kisselev S; Neville KA; Hoppe C; Barral S
    PLoS One; 2013; 8(2):e55709. PubMed ID: 23409025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia.
    Fitzhugh CD; Hsieh MM; Allen D; Coles WA; Seamon C; Ring M; Zhao X; Minniti CP; Rodgers GP; Schechter AN; Tisdale JF; Taylor JG
    PLoS One; 2015; 10(11):e0141706. PubMed ID: 26576059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BFU-E colony growth in response to hydroxyurea: correlation between in vitro and in vivo fetal hemoglobin induction.
    Yang YM; Pace B; Kitchens D; Ballas SK; Shah A; Baliga BS
    Am J Hematol; 1997 Dec; 56(4):252-8. PubMed ID: 9395188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term use of hydroxyurea for sickle cell anemia.
    Hagar W
    JAMA; 2003 Aug; 290(6):753; author reply 754. PubMed ID: 12915424
    [No Abstract]   [Full Text] [Related]  

  • 15. Hydroxyurea for the treatment of sickle cell anemia.
    Platt OS
    N Engl J Med; 2008 Mar; 358(13):1362-9. PubMed ID: 18367739
    [No Abstract]   [Full Text] [Related]  

  • 16. Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease.
    Wang WC
    Exp Biol Med (Maywood); 2016 Apr; 241(7):730-6. PubMed ID: 27026724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
    Adekile A; Menzel S; Gupta R; Al-Sharida S; Farag A; Haider M; Akbulut N; Mustafa N; Thein SL
    Am J Hematol; 2015 Jul; 90(7):E138-9. PubMed ID: 25851995
    [No Abstract]   [Full Text] [Related]  

  • 18. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
    Anderson N
    Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea and growth in young children with sickle cell disease.
    Rana S; Houston PE; Wang WC; Iyer RV; Goldsmith J; Casella JF; Reed CK; Rogers ZR; Waclawiw MA; Thompson B;
    Pediatrics; 2014 Sep; 134(3):465-72. PubMed ID: 25157002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea use among children with sickle cell anemia.
    Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27721. PubMed ID: 30900800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.